Eric Mayer is the CEO of EDP Biotech, a medical device company whose mission is the development and commercialization of in-vitro diagnostic tests that detect disease early. Our platform technology utilizes machine learning and multiplexing to simultaneously measure numerous proteins from a single blood draw. EDP plans to leverage its technology through strategic partnerships in the near term, followed by launching its first multi-marker blood test from the platform, ColoPlex™, used in the early detection of colorectal cancer. ColoPlex is a non-invasive, accurate, inexpensive blood test that drives the right people to confirmatory colonoscopy and reduces the overall cost of colorectal cancer screening, allowing for better patient outcomes.